Presentation Yes. So when we take a look at where we thought we'd be at the beginning of the year versus where we end up at the end of the first quarter, I think the biggest surprise was the impact of the double discounting that we had from the 340B programs on BAQSIMI. As we mentioned on our conference call, that's something where people are buying the drug at the mandated lowest price for the 340B hospitals and then still collecting a rebate when they issue it to someone who is -- has insurance coverage. ...

Amphastar Pharmaceuticals (NasdaqGS:AMPH) 2026 Conference May 13, 2026 06:00 PM ET Speaker1 Going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech at BofA, I'm pleased to be introducing Amphastar Pharmaceuticals. Joining us from Amphastar, we have Bill Peters, CFO, and Tony Marrs, Executive Vice President, Regulatory Affairs and Clinical Operations. Gentlemen, thanks for joining us. Speaker0 Thanks for having us. Speaker1 Wh ...